TriangleNCT00089076 · OUTCOME
Mean Change in % of CD3+CD4- for Marker HLA-DR+
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- percentage of change of CD3+CD4-
- Interval / dispersion
- Standard Error
- Time frame
- Before treatment to 1 month after therapy initiation
What was measured
Flow cytometric analysis of T-cell surface markers before and 1 month after initiation therapy
Analysis population: The analysis population contains patients that had peripheral blood available for analysis from before and 1 month after initiating therapy along with being able to conduct the analysis on the marker. This resulted in the number of participants analyzed being less than the enrolled participants.
Groups in this outcome
MDX-010
Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010) IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| MDX-010 | 14 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| MDX-010 | 1.9 | 2.0 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 2.0
- value
- 1.9
- denoms
- counts
- group Id
- OG000
- value
- 14
- units
- Participants
- description
- Flow cytometric analysis of T-cell surface markers before and 1 month after initiation therapy
- dispersion Type
- Standard Error
- groups
- description
- Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-010) IV over 90 minutes on day 1. Treatment repeats every 28 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- MDX-010
- param Type
- MEAN
- population Description
- The analysis population contains patients that had peripheral blood available for analysis from before and 1 month after initiating therapy along with being able to conduct the analysis on the marker. This resulted in the number of participants analyzed being less than the enrolled participants.
- reporting Status
- POSTED
- time Frame
- Before treatment to 1 month after therapy initiation
- title
- Mean Change in % of CD3+CD4- for Marker HLA-DR+
- type
- SECONDARY
- unit Of Measure
- percentage of change of CD3+CD4-
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice